WT1 126-134 Peptide Vaccine
DRACPC ID DRACPC0096
Active Ingredients WT1 126-134 Peptide Vaccine
Description A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
Synonyms WT-1: 126-134; WT1 126-134 Peptide Vaccine
Type Biotech
Disease Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence RMFPNAPYL
Sequence Length 9
Modification None
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C61442
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies | Myelodysplastic Syndrome; Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) | Phase 2 | Treatment |
| NCT00488592 | Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies | Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
